← ANALYST RATINGS · TIPRANKS
Climb Bio (CLYM): analyst forecast and price target
Analyst consensus
Strong Buy8 Buy0 Hold0 Sell
Ratings of 8 analysts in the last 3 months · top analysts only12-month forecast
Based on 8 price targets given in the last 3 months, the average target is $29.29, the highest $40.00, the lowest $18.00. The average is +198.2% from the last price of $9.82.
Analyst ratings 18
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Nevin Varghese★★★★★★★★★★#6891 · hits 100% · avg +19.2% | RBC Capital | $23.00 | Buy | +134.2% | Reiterated | 13.10.26on TipRanks 07:09 | −4.8%next day +0.9% | ↗ |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $30.00 | Buy | +205.5% | Reiterated | 12.10.26on TipRanks 07:15 | −1.5%next day −4.8% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $11.50 → $11.00−4.3% | Hold | +12.0% | Reiterated | 07.10.26on TipRanks 05:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $11.50 → $11.00−4.3% | Hold | +12.0% | Reiterated | 07.10.26on TipRanks 05:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $11.50 → $11.00−4.3% | Hold | +12.0% | Reiterated | 07.10.26on TipRanks 05:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $11.50 → $10.50−8.7% | Hold | +6.9% | Reiterated | 07.10.26on TipRanks 05:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $11.50 → $11.00−4.3% | Hold | +12.0% | Reiterated | 07.10.26on TipRanks 05:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $11.50 → $10.50−8.7% | Hold | +6.9% | Reiterated | 07.10.26on TipRanks 05:06 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $12.00 → $11.50−4.2% | Hold | +17.1% | Reiterated | 03.10.26on TipRanks Oct 2 22:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $12.00 → $11.50−4.2% | Hold | +17.1% | Reiterated | 03.10.26on TipRanks Oct 2 22:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $12.00 → $11.50−4.2% | Hold | +17.1% | Reiterated | 03.10.26on TipRanks Oct 2 22:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $12.00 → $11.50−4.2% | Hold | +17.1% | Reiterated | 03.10.26on TipRanks Oct 2 22:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $12.00 → $11.50−4.2% | Hold | +17.1% | Reiterated | 03.10.26on TipRanks Oct 2 22:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $12.00 → $11.50−4.2% | Hold | +17.1% | Reiterated | 03.10.26on TipRanks Oct 2 22:05 | — | |
| Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% | BTIG | $32.00 | Buy | +225.9% | Reiterated | 01.10.26on TipRanks Oct 2 06:16 | −3.7%next day −1.9% · 5 days −3.2% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $12.50 → $12.00−4.0% | Hold | +22.2% | Reiterated | 30.09.26on TipRanks 19:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $12.50 → $12.00−4.0% | Hold | +22.2% | Reiterated | 30.09.26on TipRanks 19:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $12.00 | Hold | +22.2% | Reiterated | 30.09.26on TipRanks 19:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $12.50 → $12.00−4.0% | Hold | +22.2% | Reiterated | 30.09.26on TipRanks 19:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $12.50 → $12.00−4.0% | Hold | +22.2% | Reiterated | 30.09.26on TipRanks 19:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $12.00 | Hold | +22.2% | Reiterated | 30.09.26on TipRanks 19:05 | — | |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $24.00 → $30.00+25.0% | Buy | +205.5% | Reiterated | 08.09.26on TipRanks 06:20 | +3.0%next day −4.9% · 5 days −11.4% | ↗ |
| Danielle Brill★★★★★★★★★★#566 · hits 56% · avg +16.1% | Truist Financial | — | Buy | — | Reiterated | 04.09.26on TipRanks 08:35 | +6.8%next day +3.0% · 5 days −5.0% | ↗ |
| Mayank Mamtani★★★★★★★★★★#2653 · hits 38% · avg +5.8% | B. Riley Securities | $26.00 → $30.00+15.4% | Buy | +205.5% | Reiterated | 04.09.26on TipRanks 08:30 | +6.8%next day +3.0% · 5 days −5.0% | ↗ |
| Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% | BTIG | $20.00 → $32.00+60.0% | Buy | +225.9% | Reiterated | 03.09.26on TipRanks 13:35 | −4.1%next day +6.8% · 5 days −1.2% | ↗ |
| Brian Skorney★★★★★★★★★★#12116 · hits 37% · avg −5.6% | Robert W. Baird | $21.00 → $25.00+19.0% | Buy | +154.6% | Reiterated | 03.09.26on TipRanks 12:55 | −4.1%next day +6.8% · 5 days −1.2% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $23.00 → $40.00+73.9% | Buy | +307.3% | Reiterated | 03.09.26on TipRanks 10:30 | −4.1%next day +6.8% · 5 days −1.2% | ↗ |
| Matt Phipps★★★★★★★★★★#2652 · hits 48% · avg +4.8% | William Blair | — | Buy | — | Reiterated | 03.09.26on TipRanks 09:55 | −4.1%next day +6.8% · 5 days −1.2% | ↗ |
| Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% | Wedbush | $20.00 | Buy | +103.7% | Reiterated | 19.08.26on TipRanks 08:55 | −0.5%next day −1.0% · 5 days −6.9% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $35.00 | Buy | +256.4% | Reiterated | 07.08.26on TipRanks Aug 10 07:35 | −0.6%next day −3.3% · 5 days +16.2% | ↗ |
| Leland Gershell★★★★★★★★★★#2332 · hits 40% · avg +6.2% | Oppenheimer | $18.00 | Buy | +83.3% | Reiterated | 07.08.26on TipRanks 08:45 | −0.6%next day −3.3% · 5 days +16.2% | ↗ |
| Nevin Varghese★★★★★★★★★★#6891 · hits 100% · avg +19.2% | RBC Capital | $23.00 | Buy | +134.2% | Reiterated | 06.08.26on TipRanks Aug 7 21:45 | +12.4%next day −0.6% · 5 days +4.0% | ↗ |
| Christopher Raymond★★★★★★★★★★#4074 · hits 45% · avg +2.6% | Raymond James | — | Buy | — | Reiterated | 24.06.26on TipRanks Jun 25 05:40 | +3.7%next day −0.9% · 5 days +2.5% | ↗ |
| Thomas Smith★★★★★★★★★★#45 · hits 57% · avg +51.1% | Leerink Partners | — | Buy | — | Reiterated | 12.06.26on TipRanks Jun 15 07:25 | +4.3%next day −1.3% · 5 days +5.9% | ↗ |
| Geulah Livshits★★★★★★★★★★#2175 · hits 35% · avg +7.2% | Chardan Capital | $22.00 | Buy | +124.0% | Initiated | 05.05.26on TipRanks May 4 23:16 | +17.4%next day +5.3% · 5 days −4.4% | ↗ |
| Joseph Catanzaro★★★★★★★★★★#981 · hits 46% · avg +13.3% | Mizuho Securities | $18.00 | Buy | +83.3% | Initiated | 15.04.26on TipRanks 04:55 | −3.0%next day +1.7% · 5 days +5.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Climb Bio
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $28.11 at a price of $11.47 (+145.1%); now: $28.11 at $9.82 (+186.3%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 15 | 15 | 14 | 9 | 9 | 9 |
| Buy | 6 | 7 | 8 | 9 | 7 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.20 (from $-0.24 to $-0.16). Last quarter: $-0.18.
Best top-analyst consensus in the sector · Healthcare
About Climb Bio
- CEO: Aoife Brennan BCh MMSc
- Employees: 28
- 20 William Street, Wellesley Hills, MA, 02481, US
- climbbio.com
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Data from the stock’s TipRanks forecast page, read 30 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗